258 related articles for article (PubMed ID: 34745152)
1. Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
Dermime S; Merhi M; Merghoub T
Front Immunol; 2021; 12():781872. PubMed ID: 34745152
[No Abstract] [Full Text] [Related]
2. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.
Xu Y; Fu Y; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():2023. PubMed ID: 33123120
[TBL] [Abstract][Full Text] [Related]
3. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series).
Sukari A; Kukreja G; Nagasaka M; Shukairy MK; Yoo G; Lin HS; Hotaling J; Kim H
Oral Oncol; 2020 Oct; 109():104744. PubMed ID: 32402656
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1.
Fan J; Shen X; Wang Y; Zhou HL; Liu G; Li YL; Xu ZX
Biomed Pharmacother; 2020 Oct; 130():110621. PubMed ID: 34321165
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review.
Petrelli F; Consoli F; Ghidini A; Perego G; Luciani A; Mercurio P; Berruti A; Grisanti S
Front Immunol; 2021; 12():720748. PubMed ID: 34616395
[TBL] [Abstract][Full Text] [Related]
6. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
Zou Y; Hu X; Zheng S; Yang A; Li X; Tang H; Kong Y; Xie X
EBioMedicine; 2021 Jan; 63():103137. PubMed ID: 33310681
[TBL] [Abstract][Full Text] [Related]
7. Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.
Zhang QJ; Luan JC; Song LB; Cong R; Ji CJ; Zhou X; Xia JD; Song NH
Front Immunol; 2021; 12():657575. PubMed ID: 33936087
[TBL] [Abstract][Full Text] [Related]
8. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
Makuku R; Khalili N; Razi S; Keshavarz-Fathi M; Rezaei N
J Immunol Res; 2021; 2021():6661406. PubMed ID: 33681388
[TBL] [Abstract][Full Text] [Related]
9. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
10. Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.
Yan C; Richmond A
Mol Cancer; 2021 Nov; 20(1):146. PubMed ID: 34758832
[TBL] [Abstract][Full Text] [Related]
11. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.
Zeng FL; Chen JF
Technol Cancer Res Treat; 2021; 20():15330338211039952. PubMed ID: 34528830
[TBL] [Abstract][Full Text] [Related]
12. Identification of immune checkpoint and cytokine signatures associated with the response to immune checkpoint blockade in gastrointestinal cancers.
Zhao C; Wu L; Liang D; Chen H; Ji S; Zhang G; Yang K; Hu Y; Mao B; Liu T; Yu Y; Zhang H; Xu J
Cancer Immunol Immunother; 2021 Sep; 70(9):2669-2679. PubMed ID: 33624146
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
[No Abstract] [Full Text] [Related]
14. Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers.
Li Y; Wang J; Wu L; Li X; Zhang X; Zhang G; Xu S; Sun S; Jiao S
Front Immunol; 2021; 12():649343. PubMed ID: 34163469
[TBL] [Abstract][Full Text] [Related]
15. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
16. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Zhang N; Wei L; Ye M; Kang C; You H
Front Immunol; 2020; 11():592612. PubMed ID: 33329578
[TBL] [Abstract][Full Text] [Related]
17. Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE; Tolaney SM
J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
[TBL] [Abstract][Full Text] [Related]
18. A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors.
Bonomi M; Bhateja P; Issa M; Klamer B; Pan X; Blakaj A; Karivedu V; Mousa L; Mitchell D; Gamez M; Kang S; Seim NB; Old M; Carrau R; Rocco J; Blakaj D
Oral Oncol; 2020 Nov; 110():104900. PubMed ID: 32702630
[TBL] [Abstract][Full Text] [Related]
19. The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis.
Ciccarese C; Iacovelli R; Bria E; Palazzo A; Maiorano BA; Mosillo C; Carbone C; Piro G; Tortora G
J Immunother; 2020 Apr; 43(3):95-103. PubMed ID: 32080018
[TBL] [Abstract][Full Text] [Related]
20. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
Barroso-Sousa R; Tolaney SM
Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]